Pentixapharm Holding AG Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	0.07	0.09	6.82
Revenue Growth	-	-98.64%	-
Gross Profit	0.07	0.09	6.82
Selling, General & Admin	6.36	6.52	1.43
Depreciation & Amortization Expenses	3.7	3.73	19.04
Research & Development	6.09	6.8	3.72
Other Operating Expenses	2.67	2.91	-0.4
Total Operating Expenses	18.83	19.95	23.79
Operating Income	-18.76	-19.86	-16.97
Total Non-Operating Income (Expense)	0.17	0.35	0.42
Pretax Income	-18.58	-19.51	-16.55
Provision for Income Taxes	-2.9	-3	-4.62
Net Income	-15.68	-16.51	-11.93
Net Income to Common	-15.68	-16.51	-11.93
Net Income Growth	-	-	-
Shares Outstanding (Basic)	25	25	25
Shares Outstanding (Diluted)	25	25	25
Shares Change	-	-	-
EPS (Basic)	-0.64	-0.67	-0.52
EPS (Diluted)	-0.64	-0.67	-0.52
EPS Growth	-	-	-
Free Cash Flow	-15.2	-17.97	0
Free Cash Flow Growth	-	-	-
Free Cash Flow Per Share	-0.61	-0.73	-
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-25347.30%	-21354.80%	-248.93%
Profit Margin	-21187.80%	-17753.80%	-174.93%
FCF Margin	-20544.60%	-19325.80%	0.00%
EBITDA	-15.05	-16.13	-16.97
EBITDA Margin	-20341.90%	-17344.10%	-248.93%
EBIT	-18.76	-19.86	-16.97
EBIT Margin	-25347.30%	-21354.80%	-248.93%
Effective Tax Rate	15.63%	15.38%	27.93%